Status:
COMPLETED
A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This randomized, double-blind, multi-center, placebo-controlled, parallel-group study will evaluate the sustained virologic response and the safety of mericitabine (RO5024048) in combination with boce...
Eligibility Criteria
Inclusion
- Adult patients, \>/=18 years of age
- Chronic hepatitis C infection for at least 6 months duration
- Hepatitis C genotype 1a or 1b
- Patients must have discontinued prior hepatitis C treatment at least 12 weeks prior to enrollment in this study
- Patient showed a previous null response to therapy as defined by \< 2 log10 IU/mL decrease in viral titer after at least 12 weeks of treatment with PEG-IFN/RBV
Exclusion
- Hepatitis C infection with a genotype other than genotype 1a or 1b
- Body mass index \<18 or \>/=36
- Hepatitis A, hepatitis B, or HIV infection
- Herbal remedies \</=1 month prior to the first dose of study drug
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT01482403
Start Date
November 1 2011
End Date
January 1 2014
Last Update
August 5 2016
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Littleton, Colorado, United States, 80120
2
Chicago, Illinois, United States, 60637
3
Shreveport, Louisiana, United States, 71130
4
Detroit, Michigan, United States, 48202